T. Ketas

发表

HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy.

A. Trkola, J. Moore, D. Ho, 1999, The Journal of clinical investigation.

A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies

John P. Moore, I. Wilson, T. Ketas, 2013, PLoS pathogens.

Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens

D. Baker, John P. Moore, T. Ketas, 2020, bioRxiv.

Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle

D. Baker, J. Bale, John P. Moore, 2019, Nature Communications.

Neutralizing Antibody Induction by HIV-1 Envelope Glycoprotein SOSIP Trimers on Iron Oxide Nanoparticles May Be Impaired by Mannose Binding Lectin

John P. Moore, I. Wilson, M. Nussenzweig, 2019, Journal of Virology.

Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor.

John P. Moore, T. Ketas, R. Veazey, 2010, The Journal of infectious diseases.

HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use

A. Trkola, John P. Moore, T. Ketas, 2002, Proceedings of the National Academy of Sciences of the United States of America.

The Differential Sensitivity of Human and Rhesus Macaque CCR5 to Small-Molecule Inhibitors of Human Immunodeficiency Virus Type 1 Entry Is Explained by a Single Amino Acid Difference and Suggests a Mechanism of Action for These Inhibitors

A. Trkola, John P. Moore, T. Ketas, 2004, Journal of Virology.

HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry.

John P. Moore, T. Ketas, A. Marozsan, 2007, Virology.

Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities.

R. Doms, John P. Moore, T. Ketas, 2009, Virology.

Inef fi cient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR 5 complex at low cell surface CCR 5 densities

R. Doms, John P. Moore, T. Ketas, 2009 .

Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C

John P. Moore, I. Wilson, D. Montefiori, 2016, PLoS pathogens.

Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes.

John P. Moore, T. Ketas, Min Lu, 2007, Virology.

cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV‐1 envelope glycoprotein vaccine candidate

E. Go, H. Desaire, John P. Moore, 2017, Biotechnology and bioengineering.

Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140

A. Trkola, John P. Moore, T. Ketas, 2001, Journal of Virology.

Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo.

John P. Moore, T. Ketas, R. Sanders, 2009, Virology.

HIV type 1 molecular clones able to use the Bonzo/STRL-33 coreceptor for virus entry.

B. Korber, J. Moore, T. Ketas, 2001, AIDS research and human retroviruses.

Predictors of Nonseroconversion after SARS-CoV-2 Infection

John P. Moore, P. Bieniasz, T. Ketas, 2021, Emerging infectious diseases.

Human Immunodeficiency Virus Type 1 Attachment, Coreceptor, and Fusion Inhibitors Are Active against both Direct and trans Infection of Primary Cells

John P. Moore, T. Ketas, P. Klasse, 2003, Journal of Virology.

Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers

John P. Moore, I. Wilson, D. Montefiori, 2017, Journal of Virology.

Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva

G. Debnath, John P. Moore, T. Ketas, 2021, Pathogens & immunity.

Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency

John P. Moore, P. Bieniasz, T. Ketas, 2020, Cell Reports Medicine.

A Native-Like SOSIP.664 Trimer Based on an HIV-1 Subtype B env Gene

John P. Moore, D. Burton, I. Wilson, 2015, Journal of Virology.

Stable 293 T and CHO cell lines expressing cleaved, stable HIV-1 envelope glycoprotein trimers for structural and vaccine studies

John P. Moore, T. Ketas, Helen J Kim, 2014, Retrovirology.

SARS-CoV-2 mRNA vaccination exposes progressive adaptive immune dysfunction in patients with chronic lymphocytic leukemia

T. Ketas, B. Hahn, P. Goepfert, 2022, medRxiv.

Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond

Manuel Llinás, George Papadatos, Sundari Suresh, 2016, PLoS pathogens.

Structural and biological mimicry of protein surface recognition by α/β-peptide foldamers

Min Lu, W Seth Horne, John P. Moore, 2009, Proceedings of the National Academy of Sciences.

Enhancement of α-helix mimicry by an α/β-peptide foldamer via incorporation of a dense ionic side-chain array.

John P. Moore, T. Ketas, S. Gellman, 2012, Journal of the American Chemical Society.

Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency

John P. Moore, T. Ketas, F. Bonelli, 2009, Proceedings of the National Academy of Sciences.

Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients

John P. Moore, T. Ketas, L. Westblade, 2021, Biosensors and Bioelectronics.

Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients

J. Moore, T. Ketas, L. Westblade, 2020, medRxiv.

Analysis of the Mechanism by Which the Small-Molecule CCR5 Antagonists SCH-351125 and SCH-350581 Inhibit Human Immunodeficiency Virus Type 1 Entry

Thomas P. Sakmar, Christoph Seibert, A. Trkola, 2003, Journal of Virology.

Serologic response to mRNA COVID‐19 vaccination in lymphoma patients

J. Leonard, John P. Moore, T. Ketas, 2021, American journal of hematology.

Partial protection against multiple RT-SHIV162P3 vaginal challenge of rhesus macaques by a silicone elastomer vaginal ring releasing the NNRTI MC1220.

Ronald S Veazey, Diarmaid J. Murphy, Laurie Goldman, 2013, The Journal of antimicrobial chemotherapy.

HIV-1 evades virus-specific IgG2 and IgA class switching by targeting systemic and intestinal B cells via long-range intercellular conduits

T. Ketas, R. Sanders, L. Cohen-Gould, 2009, Nature Immunology.

Postconvalescent SARS-CoV-2 IgG and Neutralizing Antibodies are Elevated in Individuals with Poor Metabolic Health

John P. Moore, T. Ketas, Zhengming Chen, 2021, The Journal of clinical endocrinology and metabolism.

Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus–cell fusion

John P. Moore, T. Ketas, R. Veazey, 2005, Nature.

Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes

Andrew B. Ward, Ian A. Wilson, David C. Montefiori, 2018, Journal of Virology.

Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors.

John P. Moore, T. Ketas, P. Klasse, 2012, Virology.

The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4.

B. Korber, John P. Moore, Steven Wolinsky, 2004, Virology.

The CC-Chemokine RANTES Increases the Attachment of Human Immunodeficiency Virus Type 1 to Target Cells via Glycosaminoglycans and Also Activates a Signal Transduction Pathway That Enhances Viral Infectivity

A. Trkola, John P. Moore, T. Ketas, 1999, Journal of Virology.

Enhances Viral Infectivity Signal Transduction Pathway That Glycosaminoglycans and Also Activates a Virus Type 1 to Target Cells via Attachment of Human Immunodeficiency The CC-Chemokine RANTES Increases the

Amanda, A. Trkola, John P. Moore, 1999 .

Longitudinal antibody response kinetics following SARS-CoV-2 messenger RNA vaccination in pregnant and nonpregnant persons

Iman A. Mohammed, John P. Moore, T. Ketas, 2022, American Journal of Obstetrics & Gynecology MFM.

Treatment of Advanced Human Immunodeficiency Virus Type 1 Disease with the Viral Entry Inhibitor PRO 542

John P. Moore, C. Petropoulos, T. Ketas, 2004, Antimicrobial Agents and Chemotherapy.

D-101 HIV-1 neutralizing antibodies induced by native-like envelope trimers

G. Debnath, John P. Moore, D. Burton, 2016 .

Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120

John P. Moore, D. Burton, T. Ketas, 2003, Nature Medicine.

Sustained Release of the CCR5 Inhibitors CMPD167 and Maraviroc from Vaginal Rings in Rhesus Macaques

Diarmaid J. Murphy, John P. Moore, T. Ketas, 2012, Antimicrobial Agents and Chemotherapy.

The CCR5 and CXCR4 Coreceptors Are Both Used by Human Immunodeficiency Virus Type 1 Primary Isolates from Subtype C

Lynn Morris, William C. Olson, Mia Coetzer, 2003, Journal of Virology.

The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection.

A. Trkola, D. Richman, J. Moore, 2000, The Journal of infectious diseases.

Conformational antigenic heterogeneity as a cause of the persistent fraction in HIV-1 neutralization

John P. Moore, T. Ketas, G. Ozorowski, 2023, Research square.

The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization

John P. Moore, D. Montefiori, H. Schuitemaker, 2021, Journal of virology.

T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers

Bertrand Z. Yeung, Madeleine K. D. Scott, B. Pulendran, 2020, Nature Medicine.

T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers

Bertrand Z. Yeung, Madeleine K. D. Scott, B. Pulendran, 2020, Nature Medicine.

Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types.

John P. Moore, T. Ketas, G. Reyes, 2003, AIDS research and human retroviruses.

High-resolution mapping of the neutralizing and binding specificities of polyclonal rabbit serum elicited by HIV Env trimer immunization

Sarah K. Hilton, John P. Moore, J. Bloom, 2020, bioRxiv.

High-resolution mapping of the neutralizing and binding specificities of polyclonal sera post-HIV Env trimer vaccination

Sarah K. Hilton, John P. Moore, J. Bloom, 2021, eLife.

Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques

B. Pulendran, G. Debnath, John P. Moore, 2018, PLoS pathogens.

Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands.

John P. Moore, T. Ketas, P. Klasse, 2007, Virology.

A. Trkola, John P. Moore, T. Ketas, 2004, Journal of Virology.

A General Strategy to Endow Natural Fusion-protein-Derived Peptides with Potent Antiviral Activity

R. Cortese, T. Ketas, M. Porotto, 2012, PloS one.

Improving the Immunogenicity of Native-like HIV-1 Envelope Trimers by Hyperstabilization

E. Go, H. Desaire, John P. Moore, 2017, Cell reports.

Antibody responses to SARS-CoV-2 mRNA vaccines are detectable in saliva

G. Debnath, John P. Moore, T. Ketas, 2021, bioRxiv.

Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41

John P. Moore, T. Ketas, C. Anastassopoulou, 2009, Proceedings of the National Academy of Sciences.

Stable 293 T and CHO cell lines expressing cleaved, stable HIV-1 envelope glycoprotein trimers for structural and vaccine studies

John P. Moore, I. Wilson, T. Ketas, 2014, Retrovirology.

N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus.

R. Doms, John P. Moore, T. Ketas, 2008, Virology.

Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults.

A. Trkola, T. Ketas, I. Lowy, 2000, The Journal of infectious diseases.

Use of a Small Molecule CCR5 Inhibitor in Macaques to Treat Simian Immunodeficiency Virus Infection or Prevent Simian–Human Immunodeficiency Virus Infection

R. Doms, John P. Moore, Steven Wolinsky, 2003, The Journal of experimental medicine.

Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study

T. Ketas, B. Hahn, P. Goepfert, 2023, PLoS medicine.

Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41.

John P. Moore, T. Ketas, C. Anastassopoulou, 2011, Virology.

Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors.

Elizabeth Michael, John P. Moore, T. Ketas, 2008, Virology.

Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor.

John P. Moore, T. Ketas, Min Lu, 2007, Biochemistry.

Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance.

John P. Moore, T. Ketas, C. Anastassopoulou, 2012, Virology.

Resistance to CCR 5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp 41

John P. Moore, T. Ketas, C. Anastassopoulou, 2009 .

Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo.

John P. Moore, T. Ketas, R. Sanders, 2009, Virology.

Enhancement of alpha-helix mimicry by an alpha / beta-peptide foldamer via incorporation of a dense ionic side-chain array.

John P. Moore, T. Ketas, S. Gellman, 2012 .

A Native-Like SOSIP.664 Trimer Based on an HIV-1 Subtype B env Gene

John P. Moore, D. Burton, I. Wilson, 2015, Journal of Virology.

HIV-1 neutralizing antibodies induced by native-like envelope trimers

John P. Moore, M. V. van Breemen, D. Montefiori, 2015, Science.

Glycan heterogeneity as a cause of the persistent fraction in HIV-1 neutralization

John P. Moore, T. Ketas, K. Rantalainen, 2023, bioRxiv.

Conformational antigenic heterogeneity as a cause of the persistent fraction in HIV-1 neutralization

John P. Moore, T. Ketas, G. Ozorowski, 2023, Retrovirology.

Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques

B. Pulendran, John P. Moore, I. Wilson, 2018, PLoS pathogens.

Partial protection against multiple RT-SHIV162P3 vaginal challenge of rhesus macaques by a silicone elastomer vaginal ring releasing the NNRTI MC1220.

Diarmaid J. Murphy, John P. Moore, T. Ketas, 2013, The Journal of antimicrobial chemotherapy.

Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors.

John P. Moore, T. Ketas, P. Klasse, 2012, Virology.